JP2002543093A5 - - Google Patents

Info

Publication number

JP2002543093A5

JP2002543093A5 JP2000614295A JP2000614295A JP2002543093A5 JP 2002543093 A5 JP2002543093 A5 JP 2002543093A5 JP 2000614295 A JP2000614295 A JP 2000614295A JP 2000614295 A JP2000614295 A JP 2000614295A JP 2002543093 A5 JP2002543093 A5 JP 2002543093A5

Authority

JP

Japan

Prior art keywords

vegf

antibody

antibodies

vegfr2

tumor

Prior art date

2000-04-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 348
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 346
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 344
• 206010028980 Neoplasm Diseases 0.000 description 271
• 238000000034 method Methods 0.000 description 211
• 230000027455 binding Effects 0.000 description 198
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 152
• 241001465754 Metazoa Species 0.000 description 133
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 130
• 210000004027 cell Anatomy 0.000 description 129
• 241000282414 Homo sapiens Species 0.000 description 125
• 239000003814 drug Substances 0.000 description 118
• 239000000427 antigen Substances 0.000 description 112
• 108091007433 antigens Proteins 0.000 description 112
• 102000036639 antigens Human genes 0.000 description 112
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 111
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 105
• 239000012634 fragment Substances 0.000 description 94
• 108090000623 proteins and genes Proteins 0.000 description 85
• 238000011282 treatment Methods 0.000 description 80
• 239000000203 mixture Substances 0.000 description 78
• 239000003795 chemical substances by application Substances 0.000 description 75
• 102000005962 receptors Human genes 0.000 description 72
• 108020003175 receptors Proteins 0.000 description 72
• 230000033115 angiogenesis Effects 0.000 description 71
• 238000002399 angioplasty Methods 0.000 description 68
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 61
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 60
• 238000003556 assay Methods 0.000 description 59
• 239000000306 component Substances 0.000 description 58
• 229940124597 therapeutic agent Drugs 0.000 description 58
• 201000010099 disease Diseases 0.000 description 55
• 210000002889 endothelial cell Anatomy 0.000 description 52
• 210000005166 vasculature Anatomy 0.000 description 52
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 50
• 108091008605 VEGF receptors Proteins 0.000 description 47
• 108060003951 Immunoglobulin Proteins 0.000 description 46
• 230000000903 blocking effect Effects 0.000 description 46
• 102000018358 immunoglobulin Human genes 0.000 description 46
• 230000000694 effects Effects 0.000 description 45
• 230000001225 therapeutic effect Effects 0.000 description 45
• 230000002401 inhibitory effect Effects 0.000 description 43
• 102000004169 proteins and genes Human genes 0.000 description 43
• 229940079593 drug Drugs 0.000 description 42
• 210000004408 hybridoma Anatomy 0.000 description 41
• 229940127121 immunoconjugate Drugs 0.000 description 39
• 230000000259 anti-tumor effect Effects 0.000 description 38
• 239000013598 vector Substances 0.000 description 37
• 230000008901 benefit Effects 0.000 description 34
• 210000004204 blood vessel Anatomy 0.000 description 33
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 32
• 239000000032 diagnostic agent Substances 0.000 description 32
• 229940039227 diagnostic agent Drugs 0.000 description 32
• 210000001519 tissue Anatomy 0.000 description 32
• 210000004881 tumor cell Anatomy 0.000 description 32
• 210000002997 osteoclast Anatomy 0.000 description 31
• 239000003446 ligand Substances 0.000 description 30
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 29
• 230000014509 gene expression Effects 0.000 description 29
• 210000002540 macrophage Anatomy 0.000 description 29
• 238000004519 manufacturing process Methods 0.000 description 29
• 239000000651 prodrug Substances 0.000 description 28
• 229940002612 prodrug Drugs 0.000 description 28
• 241000699670 Mus sp. Species 0.000 description 27
• 230000002491 angiogenic effect Effects 0.000 description 27
• 210000000628 antibody-producing cell Anatomy 0.000 description 27
• 238000000338 in vitro Methods 0.000 description 27
• 230000001404 mediated effect Effects 0.000 description 27
• 238000012360 testing method Methods 0.000 description 27
• 239000003053 toxin Substances 0.000 description 27
• 108020004414 DNA Proteins 0.000 description 26
• 201000011510 cancer Diseases 0.000 description 25
• 230000006870 function Effects 0.000 description 25
• 230000008685 targeting Effects 0.000 description 25
• 231100000765 toxin Toxicity 0.000 description 25
• 108700012359 toxins Proteins 0.000 description 25
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 24
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 24
• 150000007523 nucleic acids Chemical group 0.000 description 24
• 230000008569 process Effects 0.000 description 24
• 238000001727 in vivo Methods 0.000 description 23
• 210000004698 lymphocyte Anatomy 0.000 description 23
• 230000001772 anti-angiogenic effect Effects 0.000 description 22
• 210000000845 cartilage Anatomy 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 21
• 239000004037 angiogenesis inhibitor Substances 0.000 description 21
• 230000003053 immunization Effects 0.000 description 21
• 230000015572 biosynthetic process Effects 0.000 description 20
• 239000002596 immunotoxin Substances 0.000 description 20
• 235000018102 proteins Nutrition 0.000 description 20
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 19
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 19
• 239000003114 blood coagulation factor Substances 0.000 description 19
• 230000004663 cell proliferation Effects 0.000 description 19
• 102000039446 nucleic acids Human genes 0.000 description 19
• 108020004707 nucleic acids Proteins 0.000 description 19
• 239000008194 pharmaceutical composition Substances 0.000 description 19
• 108090000765 processed proteins & peptides Proteins 0.000 description 19
• 239000002246 antineoplastic agent Substances 0.000 description 18
• 230000005764 inhibitory process Effects 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 18
• 239000000523 sample Substances 0.000 description 17
• 230000009261 transgenic effect Effects 0.000 description 17
• 102000004190 Enzymes Human genes 0.000 description 16
• 108090000790 Enzymes Proteins 0.000 description 16
• 150000001875 compounds Chemical class 0.000 description 16
• 210000003038 endothelium Anatomy 0.000 description 16
• 229940088598 enzyme Drugs 0.000 description 16
• 230000002163 immunogen Effects 0.000 description 16
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 15
• 108010079505 Endostatins Proteins 0.000 description 15
• 235000001014 amino acid Nutrition 0.000 description 15
• 229940127089 cytotoxic agent Drugs 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 238000006366 phosphorylation reaction Methods 0.000 description 15
• 238000002965 ELISA Methods 0.000 description 14
• 229940024606 amino acid Drugs 0.000 description 14
• 150000001413 amino acids Chemical class 0.000 description 14
• 210000003719 b-lymphocyte Anatomy 0.000 description 14
• 230000004927 fusion Effects 0.000 description 14
• 229940072221 immunoglobulins Drugs 0.000 description 14
• 230000011664 signaling Effects 0.000 description 14
• 108010000499 Thromboplastin Proteins 0.000 description 13
• 102000002262 Thromboplastin Human genes 0.000 description 13
• 125000003275 alpha amino acid group Chemical group 0.000 description 13
• 230000007423 decrease Effects 0.000 description 13
• 230000002601 intratumoral effect Effects 0.000 description 13
• 230000035699 permeability Effects 0.000 description 13
• 230000026731 phosphorylation Effects 0.000 description 13
• 238000012216 screening Methods 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 241000724791 Filamentous phage Species 0.000 description 12
• 241000124008 Mammalia Species 0.000 description 12
• 210000002808 connective tissue Anatomy 0.000 description 12
• 230000002792 vascular Effects 0.000 description 12
• 230000008728 vascular permeability Effects 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 11
• 230000012292 cell migration Effects 0.000 description 11
• 239000000701 coagulant Substances 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 238000002649 immunization Methods 0.000 description 11
• 229940051026 immunotoxin Drugs 0.000 description 11
• 230000002637 immunotoxin Effects 0.000 description 11
• 231100000608 immunotoxin Toxicity 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• 238000013508 migration Methods 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 230000004083 survival effect Effects 0.000 description 11
• 241000283973 Oryctolagus cuniculus Species 0.000 description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 230000002022 anti-cellular effect Effects 0.000 description 10
• 239000003124 biologic agent Substances 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 230000015271 coagulation Effects 0.000 description 10
• 238000005345 coagulation Methods 0.000 description 10
• 230000006378 damage Effects 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 239000003102 growth factor Substances 0.000 description 10
• 201000000050 myeloid neoplasm Diseases 0.000 description 10
• 102000004196 processed proteins & peptides Human genes 0.000 description 10
• 241000894007 species Species 0.000 description 10
• 210000000952 spleen Anatomy 0.000 description 10
• 230000000638 stimulation Effects 0.000 description 10
• 210000003556 vascular endothelial cell Anatomy 0.000 description 10
• -1 vasculostatin Proteins 0.000 description 10
• 108091026890 Coding region Proteins 0.000 description 9
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 9
• 241000283984 Rodentia Species 0.000 description 9
• 108700019146 Transgenes Proteins 0.000 description 9
• 125000000539 amino acid group Chemical group 0.000 description 9
• 230000003527 anti-angiogenesis Effects 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 230000001338 necrotic effect Effects 0.000 description 9
• 229920001184 polypeptide Polymers 0.000 description 9
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 230000001093 anti-cancer Effects 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 238000000975 co-precipitation Methods 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 238000003752 polymerase chain reaction Methods 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 210000004989 spleen cell Anatomy 0.000 description 8
• 230000004614 tumor growth Effects 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 108010029485 Protein Isoforms Proteins 0.000 description 7
• 102000001708 Protein Isoforms Human genes 0.000 description 7
• 239000002671 adjuvant Substances 0.000 description 7
• 230000006907 apoptotic process Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000000539 dimer Substances 0.000 description 7
• 239000012636 effector Substances 0.000 description 7
• 230000001900 immune effect Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 238000001959 radiotherapy Methods 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 108010039491 Ricin Proteins 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 230000008512 biological response Effects 0.000 description 6
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 6
• 238000002825 functional assay Methods 0.000 description 6
• 102000058223 human VEGFA Human genes 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 125000005647 linker group Chemical group 0.000 description 6
• 230000022275 macrophage chemotaxis Effects 0.000 description 6
• 238000012423 maintenance Methods 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 230000003472 neutralizing effect Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 125000006850 spacer group Chemical group 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 230000005747 tumor angiogenesis Effects 0.000 description 6
• 206010003445 Ascites Diseases 0.000 description 5
• 108060005980 Collagenase Proteins 0.000 description 5
• 102000029816 Collagenase Human genes 0.000 description 5
• 108700024394 Exon Proteins 0.000 description 5
• 206010021143 Hypoxia Diseases 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 206010028851 Necrosis Diseases 0.000 description 5
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 229920002684 Sepharose Polymers 0.000 description 5
• 206010054094 Tumour necrosis Diseases 0.000 description 5
• 230000003213 activating effect Effects 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 229960002424 collagenase Drugs 0.000 description 5
• 239000000824 cytostatic agent Substances 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 231100000599 cytotoxic agent Toxicity 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 210000003989 endothelium vascular Anatomy 0.000 description 5
• 238000009396 hybridization Methods 0.000 description 5
• 230000016784 immunoglobulin production Effects 0.000 description 5
• 238000001114 immunoprecipitation Methods 0.000 description 5
• 238000002955 isolation Methods 0.000 description 5
• 230000004807 localization Effects 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 230000017074 necrotic cell death Effects 0.000 description 5
• 238000002823 phage display Methods 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 4
• 102100037362 Fibronectin Human genes 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000753253 Homo sapiens Tyrosine-protein kinase receptor Tie-1 Proteins 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 description 4
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
• 229960003896 aminopterin Drugs 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 238000011122 anti-angiogenic therapy Methods 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000035605 chemotaxis Effects 0.000 description 4
• 230000004186 co-expression Effects 0.000 description 4
• 229960001338 colchicine Drugs 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• 231100000433 cytotoxic Toxicity 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 238000002405 diagnostic procedure Methods 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 230000013020 embryo development Effects 0.000 description 4
• 230000009088 enzymatic function Effects 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 206010023332 keratitis Diseases 0.000 description 4
• 238000011813 knockout mouse model Methods 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 238000004091 panning Methods 0.000 description 4
• 238000011002 quantification Methods 0.000 description 4
• 230000003439 radiotherapeutic effect Effects 0.000 description 4
• 230000009257 reactivity Effects 0.000 description 4
• 238000003259 recombinant expression Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 102000035025 signaling receptors Human genes 0.000 description 4
• 108091005475 signaling receptors Proteins 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 4
• 229960003048 vinblastine Drugs 0.000 description 4
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 3
• LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 3
• 102000009840 Angiopoietins Human genes 0.000 description 3
• 108010009906 Angiopoietins Proteins 0.000 description 3
• 102400000068 Angiostatin Human genes 0.000 description 3
• 108010079709 Angiostatins Proteins 0.000 description 3
• 101710132601 Capsid protein Proteins 0.000 description 3
• 241000700198 Cavia Species 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 102100023804 Coagulation factor VII Human genes 0.000 description 3
• 101710094648 Coat protein Proteins 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 101150021185 FGF gene Proteins 0.000 description 3
• 108010023321 Factor VII Proteins 0.000 description 3
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 101710125418 Major capsid protein Proteins 0.000 description 3
• 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 3
• 101710141454 Nucleoprotein Proteins 0.000 description 3
• 229930012538 Paclitaxel Natural products 0.000 description 3
• 108090000778 Platelet factor 4 Proteins 0.000 description 3
• 102000004211 Platelet factor 4 Human genes 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 101710083689 Probable capsid protein Proteins 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000007720 allelic exclusion Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 3
• 229950011321 azaserine Drugs 0.000 description 3
• 230000017531 blood circulation Effects 0.000 description 3
• 230000004097 bone metabolism Effects 0.000 description 3
• 230000011712 cell development Effects 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 230000002759 chromosomal effect Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000001066 destructive effect Effects 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 235000013601 eggs Nutrition 0.000 description 3
• 210000002257 embryonic structure Anatomy 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 229940012413 factor vii Drugs 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002452 interceptive effect Effects 0.000 description 3
• 238000010253 intravenous injection Methods 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 238000007500 overflow downdraw method Methods 0.000 description 3
• 229960001592 paclitaxel Drugs 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000013615 primer Substances 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 3
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• 108020005029 5' Flanking Region Proteins 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
• 102100034608 Angiopoietin-2 Human genes 0.000 description 2
• 108010048036 Angiopoietin-2 Proteins 0.000 description 2
• 108010064733 Angiotensins Proteins 0.000 description 2
• 102000015427 Angiotensins Human genes 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 102400000730 Canstatin Human genes 0.000 description 2
• 101800000626 Canstatin Proteins 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102100022641 Coagulation factor IX Human genes 0.000 description 2
• 206010053567 Coagulopathies Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 101150097493 D gene Proteins 0.000 description 2
• 238000009007 Diagnostic Kit Methods 0.000 description 2
• 108010024212 E-Selectin Proteins 0.000 description 2
• 102100023471 E-selectin Human genes 0.000 description 2
• 102000012085 Endoglin Human genes 0.000 description 2
• 108010036395 Endoglin Proteins 0.000 description 2
• 108091008794 FGF receptors Proteins 0.000 description 2
• 108010076282 Factor IX Proteins 0.000 description 2
• 108010048049 Factor IXa Proteins 0.000 description 2
• 108010054265 Factor VIIa Proteins 0.000 description 2
• 108010014173 Factor X Proteins 0.000 description 2
• 108010074860 Factor Xa Proteins 0.000 description 2
• 108010073385 Fibrin Proteins 0.000 description 2
• 102000009123 Fibrin Human genes 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 2
• 229920002971 Heparan sulfate Polymers 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 102000005741 Metalloproteases Human genes 0.000 description 2
• 108010006035 Metalloproteases Proteins 0.000 description 2
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 108091008103 RNA aptamers Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010005173 SERPIN-B5 Proteins 0.000 description 2
• 102100030333 Serpin B5 Human genes 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 108090000054 Syndecan-2 Proteins 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
• 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 229930003448 Vitamin K Natural products 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 238000012867 alanine scanning Methods 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 230000005744 arteriovenous malformation Effects 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 230000000711 cancerogenic effect Effects 0.000 description 2
• 150000001720 carbohydrates Chemical group 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000007910 cell fusion Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 230000035602 clotting Effects 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 150000004814 combretastatins Chemical class 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
• 229960004222 factor ix Drugs 0.000 description 2
• 229940012414 factor viia Drugs 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 230000036252 glycation Effects 0.000 description 2
• 108010038082 heparin proteoglycan Proteins 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000001146 hypoxic effect Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 239000003999 initiator Substances 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 238000000021 kinase assay Methods 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000008450 motivation Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• 230000011164 ossification Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 210000002741 palatine tonsil Anatomy 0.000 description 2
• 210000004976 peripheral blood cell Anatomy 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 239000006152 selective media Substances 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 239000011885 synergistic combination Substances 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 239000013638 trimer Substances 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 235000019168 vitamin K Nutrition 0.000 description 2
• 239000011712 vitamin K Substances 0.000 description 2
• 150000003721 vitamin K derivatives Chemical class 0.000 description 2
• 229940046010 vitamin k Drugs 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 102000000412 Annexin Human genes 0.000 description 1
• 108050008874 Annexin Proteins 0.000 description 1
• 241000269350 Anura Species 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 208000018380 Chemical injury Diseases 0.000 description 1
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 206010011017 Corneal graft rejection Diseases 0.000 description 1
• 206010055665 Corneal neovascularisation Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 229910052692 Dysprosium Inorganic materials 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 208000019878 Eales disease Diseases 0.000 description 1
• 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 229910052691 Erbium Inorganic materials 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 241001524679 Escherichia virus M13 Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010029144 Factor IIa Proteins 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
• GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
• 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
• 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
• 206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108700015690 Immunoglobulin Switch Region Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 101150008942 J gene Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 102000016551 L-selectin Human genes 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 108010011756 Milk Proteins Proteins 0.000 description 1
• 102000014171 Milk Proteins Human genes 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 101100013458 Mus musculus Ftl1 gene Proteins 0.000 description 1
• 206010062207 Mycobacterial infection Diseases 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 241001460678 Napo <wasp> Species 0.000 description 1
• 101710204212 Neocarzinostatin Proteins 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102100028762 Neuropilin-1 Human genes 0.000 description 1
• 108090000772 Neuropilin-1 Proteins 0.000 description 1
• VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000004788 Pars Planitis Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 101710180074 Pepsin F Proteins 0.000 description 1
• 102000004422 Phospholipase C gamma Human genes 0.000 description 1
• 108010056751 Phospholipase C gamma Proteins 0.000 description 1
• 102100035194 Placenta growth factor Human genes 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 208000010362 Protozoan Infections Diseases 0.000 description 1
• 201000002154 Pterygium Diseases 0.000 description 1
• 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 208000007135 Retinal Neovascularization Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
• 101710145796 Staphylokinase Proteins 0.000 description 1
• 208000027073 Stargardt disease Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 229910052771 Terbium Inorganic materials 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 102100030246 Transcription factor Sp1 Human genes 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
• 101710181904 Venom factor Proteins 0.000 description 1
• 206010058990 Venous occlusion Diseases 0.000 description 1
• 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
• 208000013058 Weber syndrome Diseases 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• ARVMRLFIHCZWQT-UHFFFAOYSA-N ac1ns0qf Chemical compound [Fe+2].[Fe+2] ARVMRLFIHCZWQT-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 239000000910 agglutinin Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 239000004007 alpha amanitin Substances 0.000 description 1
• 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
• 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000005911 anti-cytotoxic effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 230000002137 anti-vascular effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
• 238000013096 assay test Methods 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 238000013357 binding ELISA Methods 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 201000007293 brain stem infarction Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 239000003710 calcium ionophore Substances 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000007398 colorimetric assay Methods 0.000 description 1
• 210000003022 colostrum Anatomy 0.000 description 1
• 235000021277 colostrum Nutrition 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 239000003145 cytotoxic factor Substances 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 238000003110 dot immunobinding assay Methods 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 231100001129 embryonic lethality Toxicity 0.000 description 1
• 230000035194 endochondral ossification Effects 0.000 description 1
• 229940124642 endogenous agent Drugs 0.000 description 1
• 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
• 230000009762 endothelial cell differentiation Effects 0.000 description 1
• 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 229960003699 evans blue Drugs 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
• CBMIPXHVOVTTTL-UHFFFAOYSA-N gold(3+) Chemical compound [Au+3] CBMIPXHVOVTTTL-UHFFFAOYSA-N 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 239000000677 immunologic agent Substances 0.000 description 1
• 229940088592 immunologic factor Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 229940124541 immunological agent Drugs 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 231100000110 immunotoxic Toxicity 0.000 description 1
• 230000002625 immunotoxic effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
• APFVFJFRJDLVQX-YPZZEJLDSA-N indium-113 Chemical compound [113In] APFVFJFRJDLVQX-YPZZEJLDSA-N 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 231100000546 inhibition of ovulation Toxicity 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 238000002536 laser-induced breakdown spectroscopy Methods 0.000 description 1
• 239000010985 leather Substances 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000002197 limbic effect Effects 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 230000000938 luteal effect Effects 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 230000034217 membrane fusion Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• QSHDDOUJBYECFT-AHCXROLUSA-N mercury-197 Chemical compound [197Hg] QSHDDOUJBYECFT-AHCXROLUSA-N 0.000 description 1
• QSHDDOUJBYECFT-NJFSPNSNSA-N mercury-203 Chemical compound [203Hg] QSHDDOUJBYECFT-NJFSPNSNSA-N 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000021239 milk protein Nutrition 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 231100000299 mutagenicity Toxicity 0.000 description 1
• 230000007886 mutagenicity Effects 0.000 description 1
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
• 239000002636 mycotoxin Substances 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000017278 negative regulation of embryonic development Effects 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
• 230000004145 nucleotide salvage Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229940037201 oris Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 210000003720 plasmablast Anatomy 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
• 229960001237 podophyllotoxin Drugs 0.000 description 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000002947 procoagulating effect Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000006825 purine synthesis Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000011158 quantitative evaluation Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229910052701 rubidium Inorganic materials 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 108010073863 saruplase Proteins 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 150000003335 secondary amines Chemical group 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 201000006476 shipyard eye Diseases 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 230000007847 structural defect Effects 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001502 supplementing effect Effects 0.000 description 1
• 238000006557 surface reaction Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• BLSRSXLJVJVBIK-UHFFFAOYSA-N vanadium(2+) Chemical compound [V+2] BLSRSXLJVJVBIK-UHFFFAOYSA-N 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 239000002821 viper venom Substances 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 210000001325 yolk sac Anatomy 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1